XTX Topco Ltd Invests $521,000 in Capricor Therapeutics, Inc. (NASDAQ:CAPR)

XTX Topco Ltd acquired a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 54,870 shares of the biotechnology company's stock, valued at approximately $521,000. XTX Topco Ltd owned approximately 0.12% of Capricor Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in CAPR. Summit Investment Advisors Inc. increased its stake in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $68,000. KLP Kapitalforvaltning AS bought a new stake in Capricor Therapeutics during the fourth quarter valued at approximately $91,000. Finally, Arizona State Retirement System bought a new stake in Capricor Therapeutics during the first quarter valued at approximately $111,000. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded up $0.33 during trading hours on Thursday, reaching $8.07. The company had a trading volume of 967,053 shares, compared to its average volume of 2,983,862. Capricor Therapeutics, Inc. has a 12-month low of $3.71 and a 12-month high of $23.40. The company has a 50-day moving average price of $9.61 and a 200 day moving average price of $11.25. The firm has a market cap of $368.64 million, a price-to-earnings ratio of -5.68 and a beta of 0.59.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same period in the previous year, the firm earned ($0.31) earnings per share. As a group, research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on CAPR shares. Alliance Global Partners restated a "buy" rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. B. Riley assumed coverage on Capricor Therapeutics in a research report on Thursday, June 26th. They set a "buy" rating and a $21.00 price objective on the stock. Finally, Roth Capital dropped their target price on Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a research report on Monday, July 14th. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $22.56.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.